XELJANZ 5 mg film-coated tablets
Sponsors
Charite Universitaetsmedizin Berlin KöR, Universitaetsklinikum Erlangen AöR, Universitair Medisch Centrum Utrecht, UZ Leuven, IRCCS Istituto Giannina Gaslini
Conditions
Axial spondyloarthritisJuvenile Idiopathic ArthritisJuvenile idiopathic arthritisPatients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.Psoriatic ArthritisPsoriatic arthritisRelapsed/refractory T-cell Acute Lymphoblastic LeukemiaRheumatoid arthritis
Phase 2
Phase 3
A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
RecruitingCTIS2023-508251-39-00
Start: 2020-09-18Target: 370Updated: 2026-01-20
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA
THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
Not yet recruitingCTIS2024-517314-15-00
Target: 100Updated: 2024-09-10
SATELITE - Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis
RecruitingCTIS2024-516687-28-00
Start: 2025-06-06Target: 42Updated: 2024-11-19
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA)
Not yet recruitingCTIS2025-520923-25-00
Target: 30Updated: 2026-02-11
Phase 4
Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE
CompletedCTIS2023-505050-18-00
Start: 2023-11-16End: 2025-07-04Target: 104Updated: 2025-01-29
Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA).
CompletedCTIS2024-511401-40-00
Start: 2020-03-03End: 2025-12-09Target: 20Updated: 2024-04-03
A stratification trial to determine key immunological factors predicting Tofacitinib efficacy in Psoriatic Arthritis (PsA); TOFA-PREDICT
CompletedCTIS2024-510903-12-00
End: 2025-12-08Target: 160Updated: 2024-09-06
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.
RecruitingCTIS2024-514732-24-00
Start: 2025-04-28Target: 328Updated: 2025-08-26
REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases
RecruitingCTIS2025-520757-36-00
Start: 2025-09-15Target: 200Updated: 2026-01-13
STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial
Not yet recruitingCTIS2026-525643-32-00
Target: 224Updated: 2026-06-17
Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
Not yet recruitingCTIS2026-525221-21-01
Target: 180Updated: 2026-07-06